
Oxford Nanopore upgraded to buy with target price raised on new diagnostics deal and strategic shift.
Oxford Nanopore Technologies received a 'buy' rating upgrade from Panmure Liberum, with its target price increased to 196p from 170p. The upgrade follows a strategic pivot towards the high-value biopharma market, backed by a $20 million upfront payme...



